Literature DB >> 24247359

MiR-124 is related to podocytic adhesive capacity damage in STZ-induced uninephrectomized diabetic rats.

Dong Li1, Zhenyu Lu, Junya Jia, Zhenfeng Zheng, Shan Lin.   

Abstract

BACKGROUND: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. Podocyte plays a key role in the pathogenesis of DN. Adhesive capacity damage of podocytes is characteristic in DN. Emerging evidence suggests that microRNAs (miRNAs) play crucial roles in controlling many cell adhesion molecules thus contribute to normal cell adhesion. The roles of miRNA in podocytic adhesive capacity damage in diabetic conditions remain largely unknown.
METHODS: Diabetes was induced by tail vein injection of streptozotocin (STZ) into uninephrectomized male Wistar rats. Comparative miRNA expression array and real-time PCR analyses were conducted in sham group at week 0 (W0, n = 3) and STZ-induced uninephrectomized diabetic rats at week 1 (W1, n = 3) and week 2 (W2, n = 3) to demonstrate the greatest increased miRNA in renal cortex. At week 2, STZ-induced uninephrectomized diabetic rats were treated with vehicle (Group U, n = 9), chemically modified antisense RNA oligonucleotide (ASO) complementary to the mature miR-124 (Group O, n = 8), miR-124 mismatch control sequence (Group M, n = 8). Urine specimens were obtained for measurement of urine albumin concentration and urinary podocyte specific protein (nephrin and podocin) quantitation. Expression of integrin α3 were detected by immunohistochemistry and western blotting.
RESULTS: MiRNAs are differentially regulated in renal cortex of STZ-induced uninephrectomized diabetic rats relative to sham rats. Among the up-regulated miRNAs, miR-124 expression demonstrated the greatest increase. Administration of miR-124 ASO for two weeks significantly reduced urinary podocytic nephrin, podocin and albumin excretion and up-regulate integrin α3 expression.
CONCLUSION: MiR-124 is related to podocytic adhesive capacity damage and may be implicated in the pathogenesis of DN.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24247359     DOI: 10.1159/000355721

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  7 in total

1.  Maternal high-calorie diet is associated with altered hepatic microRNA expression and impaired metabolic health in offspring at weaning age.

Authors:  Jia Zheng; Qian Zhang; Joram D Mul; Miao Yu; Jianping Xu; Cuijuan Qi; Tong Wang; Xinhua Xiao
Journal:  Endocrine       Date:  2016-04-22       Impact factor: 3.633

Review 2.  Identification of candidate microRNA biomarkers in diabetic nephropathy: a meta-analysis of profiling studies.

Authors:  Alieh Gholaminejad; Hossein Abdul Tehrani; Mohammad Gholami Fesharaki
Journal:  J Nephrol       Date:  2018-07-17       Impact factor: 3.902

Review 3.  Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases.

Authors:  Amir Abbas Momtazi; Giuseppe Derosa; Pamela Maffioli; Maciej Banach; Amirhossein Sahebkar
Journal:  Mol Diagn Ther       Date:  2016-08       Impact factor: 4.074

Review 4.  Animal Models of Diabetes-Associated Renal Injury.

Authors:  Zahra Samadi Noshahr; Hossein Salmani; Abolfazl Khajavi Rad; Amirhossein Sahebkar
Journal:  J Diabetes Res       Date:  2020-05-20       Impact factor: 4.011

5.  Association between polymorphisms in microRNAs and susceptibility to diabetes mellitus: A meta-analysis.

Authors:  Xi Chen; Wenjing Wang; Ruien Li; Jing Yu; Lei Gao
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 6.  Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target.

Authors:  Jiahao Chen; Qinhui Liu; Jinhan He; Yanping Li
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786

Review 7.  MicroRNAs in Diabetic Kidney Disease.

Authors:  Rong Li; Arthur C K Chung; Xueqing Yu; Hui Y Lan
Journal:  Int J Endocrinol       Date:  2014-01-14       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.